KLRC1 and neoplasm: This analysis suggests that the increased affinity of highly selective anti-NKG2A KSQ mAbs may translate into substantial clinical benefits by lowering the dose, and/or reducing the dosing frequency, while retaining the saturation of receptor occupancy in tumor tissue needed to achieve optimal therapeutic anti-tumor efficacy.